Cost-benefit analysis of pharmacist interventions over 36 months in a university hospital

Maurilio de Souza CazarimI, João Paulo Vilela RodriguesI, Priscila Santos CalciniII, Thomas R. EinarsonIII, Leonardo Régis Leira PereiraI

I Universidade de São Paulo. Faculdade de Ciências Farmacêuticas de Ribeirão Preto. Ribeirão Preto, SP, Brasil
II Universidade de Ribeirão Preto. Faculdade de Ciências Farmacêuticas. Ribeirão Preto, SP, Brasil
III University of Toronto. Leslie Dan Faculty of Pharmacy. Toronto, Canada

ABSTRACT

OBJECTIVE: To perform a cost-benefits analysis of a clinical pharmacy (CP) service implemented in a Neurology ward of a tertiary teaching hospital.

METHODS: This is a cost-benefit analysis of a single arm, prospective cohort study performed at the adult Neurology Unit over 36 months, which has evaluated the results of a CP service from a hospital and Public Health System (PHS) perspective. The interventions were classified into 14 categories and the costs identified as direct medical costs. The results were analyzed by the total and marginal cost, the benefit-cost ratio (BCR) and the net benefit (NB).

RESULTS: The total 334 patients were followed-up and the highest occurrence in 506 interventions was drug introduction (29.0%). The marginal cost for the hospital and avoided cost for PHS was US$182±32 and US$25,536±4,923 per year; and US$0.55 and US$76.4 per patient/year. The BCR and NB were 0.0, -US$26,105 (95%CI -31,850 – -10,610), -US$27,112 (95%CI -33,160–11,720) for the hospital and; 3.0 (95%CI 1.97–4.94), US$51,048 (95%CI 27,645–75,716) and, 4.6 (95%CI 2.24–10.05), US$91,496 (95%CI 34,700–168,050; p < 0.001) for the PHS, both considering adhered and total interventions, respectively.

CONCLUSIONS: The CP service was not directly cost-benefit at the hospital perspective, but it presented savings for forecast cost related to the occurrence of preventable morbidities, measuring a good cost-benefit for the PHS.

DESCRIPTORS: Cost-Benefit Analysis. Pharmacy Service, Hospital. Economics, Pharmaceutical. Pharmaceutical Services.
INTRODUCTION

The most prevalent neurological diseases, especially if considered in more advanced stages, generally require pharmacological treatments, whose use is characterized by complex dosage, potential for interaction with other medication and/or the occurrence of important adverse reactions.1,2

Negative events associated with medication treatment are the cause of 5 to 10% of hospital admissions, and between 50 and 60% of these could be prevented. The responsibilities of the clinical pharmacist in the hospital environment should occur from the moment of patient admission to patient discharge. During the hospitalization period, the daily analysis of clinical evolution and medical prescriptions involve aspects that address the need for indication of pharmacological therapy, the effectiveness, and safety of treatment, among others that may be associated with unfavorable clinical outcomes.3,4

At admission and discharge, a medical reconciliation is recommended. This activity refers to the review of current medical prescriptions and evaluation of possible inconsistencies in relation to the patient’s medical history, based on prior medical prescriptions. Pharmacotherapeutic interventions can occur at these three moments: hospital admission, during hospitalization, and discharge.5–7

Scientific advances and health technologies promote an increase in the population’s life expectancy. However, an aging population poses new challenges, as there is a higher prevalence of chronic morbidities that require specialized and complex care.8 This new reality also makes it absolutely necessary to rationalize decision-making processes in order to improve the application of health resources.9 Hospital admissions due to a neurological condition represent, on average, a cost of US$718.00 per patient. If hospitalization has another primary cause, but involves concomitant neurological care, this cost can be up to five times greater.10 Studies suggest the integration of the clinical pharmacist into healthcare teams that provide care to patients with diseases such as epilepsy, Parkinson’s disease and multiple sclerosis, improves clinical outcomes and quality of life of patients assisted by means of pharmacist interventions (PI) corresponding to drug related problems (DRP). DRP may culminate in negative results of medication use.11–13

Although the clinical benefits resulting from the implementation of clinical pharmacy (CP) at different levels of healthcare are known, there is a gap that refers to the need for data-driven economic analyses of well-designed prospective studies that show the positive economic impact of the clinical pharmacist activities.14,15 In this way, evidences from benefit-cost studies are important because this design permits to assess the impact of services and programs, measuring different outcomes in monetary indicators, opposite to cost-effectiveness studies that evaluate outcomes depending on the specific clinical indicators or several outcomes by a single indicator, non-monetary, such as years of life saved.16

In this context, the aim of this study was to evaluate the cost-benefit of the CP service implemented in a Neurology ward from the perspective of the hospital and the Brazilian Public Health System (PHS).

METHODS

Study Design

We carried out a cost-benefit analysis of a single arm, prospective cohort study.12 The economic study was carried out from the hospital and PHS perspective, and composed data from patients followed-up over 36-months, from January 2013 to January 2016, without control group. Results were interpreted as marginal cost of pharmacist interventions (the purpose of CP service in Neurology ward) and the CP service cost for implementing at
Neurology ward of the hospital. Marginal cost of pharmacist interventions was estimated reasoned with and without CP services regarding pharmacist interventions. Without CP service was the cost condition that considered the hypothesis which the pharmacist interventions would not occur along the patients care at the Neurology ward, and with CP service was the cost condition over the pharmacist interventions occurred, recognized as adhered or not by medical team16,17.

**Study Location and Criteria for Patient Inclusion**

The base study for this pharmacoeconomic analysis is an open study that started in July 2012, developed at the adult ward of the Neurology Unit of the General Hospital of the Medical School of Ribeirão Preto, Universidade de São Paulo, Brazil (HCFMRP-USP). HCFMRP-USP is a tertiary hospital focused on teaching, researching, and assisting Brazilian Public Health System users12,18. The ward has 26 beds with an organizational structure that involves the following subspecialties: neuromuscular diseases, general neurology, epilepsy and movement disorders18.

In this study, we included a population of neurological patients, individuals of both genders, aged 18 years or more, who were admitted at the adult Neurology Unit of HCFMRP-USP, stayed there for at least 48 hours, and for whom at least one medication was indicated for continued use during hospitalization12.

**Clinical Pharmacy Service**

The patients included were followed-up from the time of admission to discharge. The patients’ pharmacotherapeutic follow-up was performed through daily analyses of the medical prescriptions, clinical evolutions, and laboratory tests. Upon detecting a DRP which was adapted from Strand et al.26, the clinical pharmacist made an intervention alongside the medical team, through manual and electronic medical record. The interventions were classified into 14 categories according to arrangement of the CP service and the DRP detected.

**Sample**

Sample size estimate was performed through a prevalence formula and was based on average prevalence of health team adherence to pharmacist interventions, regarding five previous studies carried out in a similar context to our study. We considered a level of significance ($\alpha$) of 5% for an infinite population; proportion of pharmacist interventions accepted from 73.4% to 98.4%; error of 0.1015. Sample size estimate was performed through a prevalence formula and was based on average prevalence of health team adherence to pharmacists’ PI, regarding five previous studies carried out in a similar context to our study. We considered a level of significance ($\alpha$) of 5% for an infinite population. Therefore, the minimum sample size required would be 134 individuals. All pharmacist interventions were accounted, but when there was no data for measuring the costs, that one was excluded.

**Data Collection**

The data were obtained through the inpatient follow-up records used by the pharmacists during follow-up and the hospital electronic system. About each patient, identification and sociodemographic data, as well as information on medication therapy and about morbidities diagnosed were collected. Regarding pharmacological therapy costs related to pharmacist interventions, data were collected on drugs prescribed to patients at the Neurology ward, such as: name of the drug, indication, pharmaceutical form, medicine dosage, route of administration, dose, and period of use. It is noteworthy the costs were estimated as a marginal cost of CP service regarding its interventions.

For each intervention, information was listed as: DRP; intervention performed; moment of intervention (reconciliation at admission, follow-up, or reconciliation at discharge);
adherence by the health team to the intervention, data on the medication involved, as described above; pre-intervention cost (without CP service); post-intervention cost (with CP service). In addition, the classification of the clinical conditions or morbidities avoided with each intervention was performed. Classification was obtained reasoned in the International Code of Diseases (ICD 10) and applied to health-related problems avoided by the corresponding interventions performed by the pharmacist.\textsuperscript{12}

Costing

Seeking a direct cost analysis we performed the mixed costing technique (micro costing and macro costing). The bottom-up and top-down methods were performed, the first being applied to the direct costs associated with the pharmacist interventions, and the second to the costs associated with co-morbidities/health complications avoided due to the pharmacist interventions, considered as prospective costs.\textsuperscript{16,17}

Identified direct medical costs were collected through the computerized system of the hospital (cost data of medical supplies, medication and exams), and assigned to each type of intervention performed. Costs related to the salary of pharmacist, nursing assistant, and nursing professionals were collected at the Human Resources department of the HCFMRP-USP. Data on outpatient costs and the respective hospitalizations of the different morbidities conditioned to the clinical conditions covered in the interventions were collected at the Tabwin Datasus\textsuperscript{\textregistered} system. These morbidity/clinical condition costs composed the estimate of PHS avoided costs by CP service, and it was interpreted like a benefit of pharmacist interventions.

Initially, cost measurement was performed for each intervention. Subsequently, the total sum for each intervention category was performed, then the annual cost and the total cost of the three years of CP service were measured. It should be noted that outpatient and inpatient costs are available for tabulation in the disenable files of the PHS Outpatient Information System (SIA-SUS) and the PHS hospital information system (SIH-SUS). These systems are used to obtain data on clinical/administrative performance in Brazilian public health. Data from all Brazilian states, between the months of January to December of 2016 were selected for a statistical analysis and then composed the avoidable clinical conditions/co-morbidities costs in our study.

Furthermore, Tabwin Datasus\textsuperscript{\textregistered} data were selected taking into consideration all the chapters of ICD 10, frequency of occurrence, and codes for classified diseases. After, the information was tabulated in the program and these data were exported to the Microsoft Excel\textsuperscript{\textregistered} program in which they were systematized in a table containing the values for diseases classified in ICD 10, and their frequency. By estimating the mean of outpatient and hospitalization values for each classification, we evaluated the outpatient/hospitalization cost forecasts related to the clinical conditions/co-morbidities possibly avoided for the PHS, a measurement of predict cost.\textsuperscript{10}

The cost of the professional to administer the medication was also considered for some interventions, whenever this type of cost had to be applied. Initially, it was measured per minute to compose the cost of the intervention to which it was assigned. The estimate was carried out by means of the average time of preparation of the drug (data collected by a questionnaire applied to the nurses that work at the neurology ward, which used the Delphi method to systematize the information as results) multiplied by the professional cost per minute worked. The 13\textsuperscript{th} salary was added to the annual cost of the professional. The cost of CP service was estimated by expenditures with one clinical pharmacist at the hospital. It was considered the professional cost, since materials and resources for implementing the service are the same existent at the Neurology ward for the common use and they could be shared.

The cost with the professionals was estimated using the data provided by the human resources department regarding each professional’s the salary and bonuses.
considered 30 hours per week for human capital; it was used mean salary pay for a pharmacist; and mean salary pay for a nurse in the state of São Paulo, Brazil. According to the Brazilian Network Health Technology Assessment, the cost sensitivity was 50% more and less than the mean estimated\(^5\).

The cost for the hospital was estimated by the marginal cost of CP service, difference between with and without CP service (without CP service would be a scenario before intervention, which was considered as the prescription or clinical conduct kept itself until the patient discharge; and with CP service was a scenario after intervention considered the changes of the prescription or clinical conduct). Box summarizes the measurement method for the PI costs considered in this study.

After the identification, measurement and valuing of the costs, the time adjustments were made. The year 2015 was used as the basis for the estimate due to data collection. However, the costs were adjusted for the year 2018. For this purpose, the National Consumer Price Index (NCPI) was considered, which is available in the consolidated economic indicators of

| Intervention categories            | Without clinical pharmacy service | With clinical pharmacy service |
|-----------------------------------|-----------------------------------|--------------------------------|
| Medication introduction           | NA                                | Cost of medication per day x time of use after intervention |
| Medication Withdrawal             | Cost of medication per day x time of use if there was no intervention | NA |
| Dose increase                     | Cost of medication per day x time of use after intervention | Cost of medication per day x time of use after intervention |
| Dose Reduction                    | Cost of medication per day x time of use after intervention | Cost of medication per day x time of use after intervention |
| Replacement                       | Cost of medication per day x time of use after intervention | Cost of medication per day x time of use after intervention |
| Administration time adjustment    | NA                                | Cost of medication per day x time of use after intervention |
| Administration route change       | Average cost of serums and diluents x number of administrations per day x time after + Professional's cost per minute x average time of IV medication administration at the hospital x time after | Cost of medication per day x time of use after intervention |
| Dosage form change                | Cost of medication per day x time of use after intervention | Cost of medication (new dosage form) per day x time of use after intervention |
| Pharmaceutical form concentration change | Cost of medication per day x time of use after intervention | Cost of medication (new presentation) per day x time of use after intervention. |
| Infusion rate change              | Average cost of serums and diluents x number of administrations per day x time after + Professional's cost per minute x average time of IV drug administration at hospital x time after | Average cost of serums and diluents x number of daily administrations x time after + professional's cost per minute x average time of IV medication administration at hospital x time after |
| Diluent change                    | Cost of diluent x number of administrations per day x time after | Cost of new diluent x number of administrations per day x time after |
| Request for examination           | NA                                | Cost of requested examination |
| Education/information             | NA                                | NA |
| Other                             | NA                                | NA |

**Box. Estimate method of clinical pharmacy service marginal cost, described for each pharmacist intervention category**

NA: not applicable. Note that a negative value for marginal cost means avoided cost for the hospital as well as for the PHS due to clinical pharmacy service, which can be interpreted as benefits. The category “Education/information” was not considered for cost estimate and has no exclusion criteria; the category “Other” was applied to that interventions not listed in the pharmacist form for interventions, then each should be analyzed individually for cost estimate and for procedures. The time after intervention was considered because this way was possible to make more coherent analysis considering that a patient can have the intervention after some days and then there is patient discharge at the day after the intervention. The estimate of professional's cost was made considering the payroll of the hospital to include the initial salary and incentive premium for the work load of 48h / day, one month of vacations, 20 days of work in the month (taken on weekends and holidays), considering the 13th salary, according to labor legislation. The annual average was performed for the nurse, nursing technician and nursing assistant. The annual compensation was divided by worked minutes in the year to get the professional minute cost. The mean time of drug preparation and administration and / or professional procedure was obtained through the Delphi method. The Delphi method is used when the data are not found in the literature with proven evidence or when the data found are controversial, it is carried out from the selection of experts in the subject where through obtaining data from their answers it is sought to predict trends. In this context, the questionnaire is used to identify the respondents' anonymity.

https://doi.org/10.11606/s1518-8787.2020054001895
the Central Bank of Brazil\textsuperscript{19}. The conversion into US dollars was made using the consolidating exchange rates for 2015 published by the Central Bank of Brazil, 1 dollar = 3.34 Reais\textsuperscript{16,17}. The estimate was made as follows in equation 1:

\[(1) \text{Time Adjustment:} \quad \text{cost} \times (1 + [\text{NCPI year of cost}]) \times (1 + [\text{NCPI year 2018}]).\]

**Analysis**

Results were analyzed by total and per patient costs. CP service marginal cost represented the additional cost involved at the pharmacist interventions for production of health facilities\textsuperscript{16}. The negative marginal cost represents a monetary benefit and positive represents no benefits. The total and annual costs of the interventions alongside with the costs of the CP service comprised the estimate of the indicators of the cost-benefit analysis for the CP service: benefit-cost ratio (BCR) of the CP service and net-benefits of the CP service for the hospital (equation 2 and 3)

\[(2) \text{BCR} = \frac{\text{benefits (marginal cost of clinical pharmacy service)}}{\text{cost (clinical pharmacy service)}} \quad \text{BCR}:
\]

\[\text{BCR} = \frac{\text{benefits (monetary from intervention costs)}}{\text{costs (Pharmaceutical service)}}\]

\[(3) \text{Net Benefit (NB):} \quad \text{NB} = \frac{\text{benefits (monetary from intervention costs) - costs (Pharmaceutical service)}}{\text{benefits (marginal cost of clinical pharmacy service) - cost (clinical pharmacy service)}}\]

For the PHS, the avoided cost of health complications was added to the marginal costs, in the equation, for composing the benefits from the PHS perspective. The indicators of the cost-benefit analysis were interpreted such as: BCR > 1 or NB > 0, the benefits were higher than the costs showing the CP service could save money; and 0 < BCR < 1 or NB < 0, the costs were higher than the benefits regarding the CP service. If the results were 1 and 0 for BCR and NB, respectively, it meant there was no difference between monetary benefits and costs. Additionally, BCR = 0 meant there was no benefit\textsuperscript{20}.

Sensitivity of BCR and NB results refer to the possible variation of direct costs of CP service, costs with medicines, human resources, which are aggregated to the marginal cost of PC service regarding pharmacist interventions and also, ambulatory and hospitalization costs with co-morbidities to the PHS. Thus, the sensitivity analysis was performed at 10,000 iterations of Monte Carlo simulation for uncertainties of costs and benefits. We used the @RISK software, version 7, of Palisade Corporation\textsuperscript{2015}. The results were interpreted for an accuracy of 5% and for adhered and total interventions.

The MINITAB version 17 statistical software was used for descriptive statistics of the estimated costs performed and summarized in the annual mean of three years of this study representation, standard deviation, minimum and maximum values and inter-quartile ranges, and also in histogram and box plot, which was important to define the probability curves of each variable. In this way, Anderson-Darling statistical test was performed, which measures how much a particular distribution fits the data; the lower this statistic, the better the distribution fits the data, the significance level of 1% was considered.

**Ethics**

This study is part of the study approved by the Research Ethics Committee of HCFMRP/USP (protocol no. 2586/2013), updated in December 2016, CAAE 29175414.8.0000.5440. Available at: http://plataformabrasil.saude.gov.br/visao/centralSuporteNova/consultarProjetoPesquisa/consultarProjetoPesquisa.jsf.
RESULTS

A total of 334 patients were followed-up by the CP service for 36 months (mean of 112 patients followed-up each year), of which 172 were women. The mean age of the patients was 51±16 years and most patients declared themselves white (n = 279). Of the total of 334 patients followed-up, there was a need for pharmacist intervention for 181 (54%) patients. Among these, most patients were men (n = 93) and the mean age was 53±16 years.

Most of the pharmacist interventions (86%) occurred during hospitalization, and the other 14% were carried out at admission or discharge. It is noteworthy that of the total interventions, the percentage of acceptance by the health team was 70%. Of the 506 interventions, that with the highest occurrence was the medication introduction, which presented the percentage of 29% of the total number of interventions.

The cost with the professionals was estimated for the mean between Nurse Assistants and Nurses which was US$5.70 per hour at the hospital and US$0.10±0.03 per minute (95%CI 0.08–0.014). Pharmacist cost was US$8,520±850 (95%CI 8,353–12,780), which considered 30 hours of work during the week that was measured for the year.

The total of the interventions resulted in a direct cost of US$3,473 for the hospital over three years, which represented an annual average of US$1,158. The marginal cost was US$182 per year, which represented the marginal cost of US$0.55 per patient/year. The cost avoided for the PHS was US$25,536 per year, US$76.40 per patient/year (Table 1).

Interventions in the medication conciliation at the hospital did not generate a direct cost impact on the hospital, but they are likely to have an impact on the PHS (Table 2).

The BCR and NB obtained from the interventions adhered to and the total of interventions showed, from the hospital perspective, there was no monetary benefit, presenting negative NB, and ratio equal to zero. However, BCR from the perspective of the PHS was 3.0 with NB of US$51,049 and 4.6 with NB equal to US$91,496, considering only the interventions adhered to and the total of interventions, respectively (Table 3).

### Table 1. Total and annual costs (US$) broken down by pharmacist intervention adhered to at moments of conciliation and follow-up by the clinical pharmacy service

| Intervention category       | Cost without CP service | Cost with CP service | CP service marginal cost (SD) | Avoided costs for the PHS (SD) |
|----------------------------|-------------------------|----------------------|-------------------------------|-------------------------------|
| Medication introduction     | 0                       | 518                  | 518                           | 26,481                        |
| Medication withdrawal       | 269                     | 0                    | -269                          | 14,789                        |
| Dose increase               | 243                     | 532                  | 290                           | 10,132                        |
| Dose reduction              | 1,962                   | 1,393                | -569                          | 7,695                         |
| Medication replacement      | 27                      | 76                   | 48                            | 4,568                         |
| Administration time adjustment | 0                      | 0                    | 0                             | 8,449                         |
| Administration route change | 32                      | 21                   | -11                           | 12                            |
| Dosage form change          | 353                     | 12                   | -341                          | 753                           |
| Pharmaceutical form concentration change | 30              | 25                   | -5                            | 178                           |
| Infusion rate change        | 9                       | 10                   | 0.6                           | 513                           |
| Examination requirement     | 0                       | 886                  | 886                           | 3,038                         |
| Other                      | 0                       | 0                    | -0.6                          | 0.6                           |
| Total                      | 2,927                   | 3,473                | 547                           | 76,609                        |
| Cost per year               | 976                     | 1,158                | 182±32                        | 25,536±4,923                  |

CP: clinical pharmacy; PHS: Public Health System; Marginal cost: (cost with clinical pharmacy service by intervention – cost without clinical pharmacy service by intervention); SD: standard deviation.

Note: Negative results in the marginal cost mean resource saving for the hospital.
The sensitivity of BCR and NB showed there was no sensitivity for the hospital as the BCR, which had no direct benefit. However, NBs were -US$26,105 (95%CI -31,850–10,610), -US$27,112 (95%CI -33,160–11,720) for adhered and total interventions (Figure, E and F). PHS had BCRs of 3.0 (95%CI 1.97–4.94), 4.6 (95%CI 2.24–10.05) and NBs of US$51,048 (95%CI 27,645–75,716), US$91,496 (95%CI 34,700–168,050) for adhered and total interventions, respectively (Figure, A, B, C and D).
This figure has grade plan because it is requested for this kind of analysis and it is make by the @Risk software. BCR: benefit-cost ratio; NB: net benefit; PHS: Public Health System.

Note: It was performed Monte Carlo simulation for 10,000 iterations and the results were interpreted for 95% of confidence. A) Amplitude of values of Benefit-cost Ratio as adhered interventions for public health system perspective; B) Amplitude of values of Benefit-cost Ratio as total interventions for public health system perspective; C) Amplitude of values of net benefit as adhered interventions for public health system perspective; D) Amplitude of values of net benefit as total interventions for public health system perspective; E) Amplitude of values of net benefit as adhered interventions for hospital perspective; F) Amplitude of values of net benefit as total interventions for hospital perspective.

Figure 1. Sensitivity analysis of benefit-cost ratio and net benefit regarding pharmacy’s clinical service.
DISCUSSION

Regarding the total number of patients included, 54% (n = 181) required one or more pharmacist interventions during the hospitalization period, generating an average of 2.7 interventions per patient, higher than that found by Nunes et al.\textsuperscript{21}. In that study, 30.4% of the patients attended at the Jamil Haddad National Institute of Traumatology and Orthopedics required the implementation of CP services.

Of the 506 interventions performed by the CP service at the adult ward of the HCFMRP-USP Neurology Unit, most interventions were accepted, generating a 70% adherence rate (n = 354). This suggests pharmacist interventions are well accepted by the health team. A similar rate was identified in the study by Gardner et al.\textsuperscript{22}, with 71% adherence to pharmacist interventions in psychiatric care and in a multicenter study conducted in France that found an acceptance rate for the intervention performed by pharmacists of 73\%\textsuperscript{23}.

It is important to highlight that in this study we measured the impact of the adhered interventions as the total of pharmacist interventions, without discussing the clinical merit in question, and that this analysis showed us an approximate difference of US$1,000 in NB for the hospital and, 35% in BCR and US$40,500 in net benefits for the PHS. In a study carried out in an intensive care unit, 98.4% of the pharmacist interventions were accepted, which generated savings of US$2,479 in CP service marginal cost\textsuperscript{24}. The CP service generated a forecast of cost savings for the PHS of US$76,609 and US$117,056, resulting from the achievements of the interventions that were adhered to and total interventions, respectively. Although CP service has not presented a positive economic impact for the hospital, outcomes were not measured. Hence, possible improvements as treatment effectiveness and quality of life could be health benefits to be assessed\textsuperscript{4,15}.

The sensitivity of these results showed even with a variation of costs to estimate monetary benefits and CP service costs the maximum NB would still be negative for the hospital, -US$10,610, there would be no monetary benefits at this perspective. However, cost savings could get up to US$48,000 per year at the PHS perspective, which was measured by BCR of 4.6 that could reach 10.5, considering total of interventions. This BCR can be compared to the fourth best strategy around the world, the control of malaria program, which had a BCR of 10.0 in 2012\textsuperscript{25}.

The management of pharmacotherapy through pharmacists’ interventions, which is difficult and complex when involving inpatients with neurological diseases, specially older ones\textsuperscript{2,26,27}, can seem costly in a simple direct cost analysis. For instance, in this study the prevalence of medicine addition was higher than withdrawal, which certainly reflected on direct hospital costs. In this way, the analysis of the perspectives of the PHS compared to the hospital perspective, showed a significant economic impact that the CP service can cause in resource savings. In CP services developed in specialized environments, it is common for interventions that introduce medication to be the majority since, as well as aiming to reduce morbidity in the short and long term, reflect the managerial action of the pharmacist for patient-centered care\textsuperscript{28}.

According to the ‘Tabwin Datasus’ system, the percentage of hospitalized patients, identified by Chapter VI – Nervous System Diseases of ICD 10 – as secondary diagnosis at the time of admission, was 2.78% in 2016 in Brazil\textsuperscript{10}. Considering this data, it is possible to extrapolate the results from this study and conjecture that this CP service evaluated would be able to impact on the national reduction of this hospitalization percentage to 2.76%. If this was implemented in the whole hospital and in other hospitals, the national impact would be higher than this difference of 0.02%.

In addition, in the year 2016 there were 15,452 national admissions of adult patients by primary diagnosis of diseases of the nervous system, which cost US$11 million for the PHS\textsuperscript{10}. Considering this scenario, alongside data from 2014 in the HCFMRP-USP neurology ward, which indicated 679 admissions, it is possible to make an analogy extrapolating the results
of this study to conjecture that approximately, US$1.8 million per year could be saved for the PHS with the implementation of this CP service at the Neurology wards at national level.

This scenario indicates substantial savings for the PHS, which could result in reallocation of resources. Brazil is the largest country in terms of population dependent on the PHS. It is noteworthy that resources used in public health are lower than the ones used in developed countries and approximately 72% of Brazilians depend on the PHS to access healthcare29.

According to the national health survey carried out in 2013 by the Brazilian Institute of Geography and Statistics of the total number of residents in Brazil, about 6.0% had a hospitalization of 24 hours or more, and of this percentage, approximately 66.0% were hospitalized at the PHS29. Thus, the implementation of the CP service can generate several benefits for the health sector, being able to reduce the hospitalization time of patients, which would result in lower expenses with medications, costs related to hospitalization, and could contribute to improve the rational use of health resources and to assist in the promotion of humanized and patient-centered care30. This is an important front to be followed within the broad perspective of healthcare, which considers the individual in all their psychosocial aspects as the target of care31,32.

There were limitations in this study as the absence of clinical records of the hospital for economic evaluation, which was responsible for reducing 12% of the sample, but even in this condition the sample was 2.5x higher than the sample plan number, approximately. Results related to clinical conditions/co-morbidities possibly avoided for the PHS had been measured by the analysis of non-treated conditions (performed by experts in medicine and CP) and had not been obtained by a conventional way like a prospective study. However, we were careful with this influence and we have considered the variation of ambulatory and hospitalization costs according to real data from Datasus. Then we believe it was reasonable for presenting robust results because pharmacist interventions that are reasoned in DRP, as in this study, are actions to improve effectiveness and avoid future health complications or co-morbidities8,26 to PHS perspective, as well as to public hospitals, although it was not measured due to this study design. Furthermore, this method may be considered efficient when we think about research efficiency in cost terms as the time for developing the study. It is noteworthy, the results showed in this study are capable of foster pharmaco-economic studies as the management of the health resources and its applicability, for instance, the saving costs for PHS could cover the costs with the CP service and its marginal cost for the hospital.

CONCLUSION

Results suggest the CP service has been well accepted by the Neurology ward health team. In this way, the CP service can be able to promote improvements in pharmacotherapeutic management at the Neurology health care. Moreover, the economic impact measured was positive for the PHS, which presented a good cost-benefit ratio and net monetary benefit. However, CP service did not represent a good cost benefit for the hospital, since there were higher costs than monetary benefits, viewed by PC service marginal cost. It is relevant to consider the amount saved for PHS could cover the hospital costs with the CP service and its marginal cost.

REFERENCES

1. Welty TE. Neurology and neurosurgery clinical pharmacy practice: ignorance, phobia or progress? Ann Pharmacother. 2006;40(12):2235-7. https://doi.org/10.1345/aph.1H495
2. Yi ZM, Sun SS, Li XX, Lu M, Zhai SD. An evaluation of clinical pharmacist service on a neurology care unit. Int J Clin Pharm. 2016;38:30-3. https://doi.org/10.1007/s11096-015-0224-y
3. Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36(7-8):1238-48. https://doi.org/10.1345/aph.1A223
4. Mergenhagen KA, Blum SS, Kugler A, Livote EE, Nebeker JR, Ott MC, et al. Pharmacist- versus physician-initiated admission medication reconciliation: impact on adverse drug events. Am J Geriatr Pharmacother. 2012;10(4):242-50. https://doi.org/10.1016/j.ajpapharm.2012.06.001

5. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63(2):136-47. https://doi.org/10.1111/j.1365-2125.2006.02698.x

6. Sekhar MS, Adheena Mary C, Anju PG, Hamsa NA. Study on drug related admissions in a tertiary care hospital in South India. Saudi Pharm J. 2011;19(4):273-8. https://doi.org/10.1016/j.jsps.2011.04.004

7. Williams M, Peterson GM, Tenni PC, Bindoff IK, Stafford AC. DOCUMENT: a system for classifying drug-related problems in community pharmacy. Int J Clin Pharm. 2012;34(1):43-52. https://doi.org/10.1007/s11096-011-9583-1

8. Gillespie U, Alassaad A, Henrohn D, Garmo H, Hammarlund-Udenaes M, Toss H, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older. Arch Intern Med. 2009;169(9):894-900. https://doi.org/10.1001/archinternmed.2009.71

9. Vieira FS. Produção de informação de custos para a tomada de decisão no Sistema Único de Saúde: uma questão para a política pública. Rio de Janeiro: Instituto de Pesquisa Econômica Aplicada - IPEA; 2017 [cited 2018 Jan 15]. (Texto para Discussão, 2314). Available from: http://www.ipea.gov.br/portaldoc/imagens/stories/PDFs/TDs/td_2314.pdf

10. Ministério da Saúde (BR), Departamento de Informática do SUS. Datasus; 2018 [cited 2018 Jul 25]. Available from: www2.datasus.gov.br/DATASUS/S/index.php?area=01

11. Hanson RL, Habibi M, Khamo N, Abdou S, Stubbing J. Integrated clinical and specialty pharmacy practice model for management of patients with multiple sclerosis. Am J Health Syst Pharm. 2014;71(6):463-9. https://doi.org/10.2146/ajhp130495

12. Rodrigues JPV, Marques FA, Gonçalves AMRF, Campos MSA, Reis TM, Morelo MRS, et al. Analysis of clinical pharmacist interventions in the Neurology Unit of a Brazilian tertiary teaching hospital. PLoS One. 2019;14(1):e0210779. https://doi:10.1371/journal.pone.0210779

13. Foppa AA, Chemello C, Vargas-Peláez CM, Farias MR. Medication therapy management service for patients with Parkinson's disease: a before-and-after study. Neurol Ther. 2016;5(1):85-99. https://doi.org/10.1007/s40120-016-0046-4

14. Kopp BJ, Mrosan M, Eristad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;64(23):2483-7. https://doi.org/10.2146/ajhp060674

15. Touchette DR, Doloresco F, Suda KJ, Perez A, Turner S, Jalundhwala Y, et al. Economic evaluations of clinical pharmacy services: 2006-2010. Pharmacotherapy. 2014;34(8):771-93. https://doi.org/10.1002/phar.1414

16. Rascati KL. Essentials of Pharmacoconomics. 2. ed. Philadelphia: Lippincott Williams & Wilkins; 2014.

17. Silva EN, Silva MT, Pereira MG. Identificação, mensuração e valoração de custos em saúde. Epidemiol Serv Saude. 2016;25(2):437-9. https://doi.org/10.5123/S1516-9479-49742016000200023

18. Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Relatório de Atividades 2017. Ribeirão Preto, SP: HCFMRP-USP; 2017 [cited 2018 Jul 31]. Available from: https://site.hcrp.usp.br/wp-content/uploads/2017/09/RelatorioDeAtividades_HCRP-2017.pdf

19. Banco Central do Brasil. Indicadores econômicos consolidados. Database. Brasília, DF; 2018 [cited 2018 Jun 27]. Available from: www.bcb.gov.br/INDECO

20. Rede Brasileira de Avaliação de Tecnologias em Saúde - REBRATS. Diretrizes metodológicas: diretizes de avaliação econômica. Brasília, DF: Ministério da Saúde; 2014 [cited 2018 Jul 31]. Available from: http://rebrats.saude.gov.br/diretrizes-metodologicas

21. Nunes PHC, Pereira BMG, Nominato JCS, Albuquerque EM, Silva LFN, Castro IRS, et al. Intervenção farmacêutica e prevenção de eventos adversos. Rev Bras Cienc Farm. 2008;44(4):691-9. https://doi.org/10.1590/S1516-93322008000400016

22. Gardner KN, Diefenderfer LA, Nelson LA, Iuppa C, Elliott E, Kleinheselink K, et al. Cost-avoidance and qualitative analysis of clinical pharmacy interventions by psychiatric pharmacy residents at state psychiatric facilities. Am J Health Syst Pharm. 2016;73(1):e46-53. https://doi.org/10.2146/ajhp130368
23. Bedouch P, Charpiat B, Conort O, Rose FX, Escobier L, Juste M, et al. Assessment of clinical pharmacists’ interventions in French hospitals: results of a multicenter study. Ann Pharmacother. 2008;42(7):1095-103. https://doi.org/10.1345/aph.1L045

24. Saokaew S, Maphanta S, Thangsomboon P. Impact of pharmacist’s interventions on cost of drug therapy in intensive care unit. Pharm Pract (Granada). 2009;7(2):81-7. https://doi.org/10.4321/s1886-36552009000200003

25. Whittington D. Benefits and costs of the water, sanitation and hygiene targets for the Post-2015 Development Agenda. Copenhagen (DNK): Copenhagen Consensus Center; 2015 [cited 2018 Oct 18]. Available from: http://www.pseau.org/outils/ouvrages/copenhagen_consensus_center_post_2015_consensus_water_resource_management_perspective_whittington_2015.pdf

26. Strand LM, Cipolle RJ, Morley PC, Frakes MJ. The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty-five years of experience. Curr Pharm Des. 2004;10(31):3987-4001. https://doi.org/10.2174/1381612043382576

27. Reeve E, Moriarty F, Nahas R, Turner JP, Kouladjian O’Donnell L, Hilmer SN. A narrative review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms. Expert Opin Drug Saf. 2018;17(1):39-49. https://doi.org/10.1080/14740338.2018.1397625

28. Bayley KB, Savitz LA, Maddalone T, Stoner SE, Hunt JS, Wells R. Evaluation of patient care interventions and recommendations by a transitional care pharmacist. Ther Clin Risk Manag. 2007;3(4):695-703.

29. Instituto Brasileiro de Geografia e Estatística. Pesquisa Nacional de Saúde 2013. Acesso e utilização dos serviços de saúde, acidentes e violência: Brasil, grandes regiões e unidades da federação. Rio de Janeiro: IBGE; 2015 [cited 2018 Jul 27]. Available from: https://biblioteca.ibge.gov.br/visualizacao/livros/liv94074.pdf

30. Gallagher J, McCarthy S, Byrne S. Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature. Int J Clin Pharm. 2014;36:1101-14. https://doi.org/10.1007/s11096-014-0008-9

31. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy. 2002;22(2):134-47. https://doi.org/10.1592/phco.22.3.134.33551

32. Youngson R, Blemmerhassett M. Humanising healthcare. BMJ. 2016;355:i6262. https://doi.org/10.1136/bmj.i62

Acknowledgement: In memoriam: PhD. Thomas Einarson, Professor Emeritus (Assoc) of the Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, ON, Canada. We thank the Health Economics and Health Technology Assessment (HEHTA) from University of Glasgow (Professor Olivia Wu) regarding PhD. stage of Maurilio de Souza Cazarim in pharmacoeconomics. To Nucleus of Evaluation of Technologies in Health of the Clinical Hospital of Ribeirão Preto, Brazil (NATS / HCRP) for providing management aid at the Clinical Hospital of Ribeirão Preto-SP and its researches. In addition, we thank the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) funding agency that provided scholarship for the author Maurilio Souza Cazarim [grant number 2017/21240-0 from January 2018 to August 2018 and grant number 2016/03584-1 from August 2016 to August 2019], URL (http://bvs.fapesp.br/en/pesquisador/673633/maurilio-de-souza-cazarim/).

Funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) funding agency has provided scholarship for the author Maurilio Souza Cazarim [grant number 2017/21240-0 from January 2018 to August 2018 and grant number 2016/03584-1 from August 2016 to August 2019], URL (http://bvs.fapesp.br/en/pesquisador/673633/maurilio-de-souza-cazarim/), thus, it has contributed for the development of this article. It highlights, the funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Opinions, assumptions and conclusions or recommendations expressed in this article are responsibility of the authors and do not necessarily reflect the viewpoint of FAPESP.

Authors’ Contribution: Conception and design of the work: MSC. Collection, analysis, and interpretation of data: MSC, JPVR, PSC. Draft or review of the manuscript: MSC, TRE. Approval of the final version: MSC, LRLP. Public responsibility for the article content: MSC, JPVR, LRLP.

Conflict of Interest: The authors declare no conflict of interest.